Saying "the time is right to bring all the various pieces together," Fulcrum Therapeutics Inc. CEO Robert Gould told BioWorld Today that his firm, funded by a $55 million series A round from Third Rock Ventures LLC, will combine recent findings in the biology of gene regulation to develop small-molecule therapies.